Actually I was mistaken. This is part of Dr. Lowe's response to a question about a MANF IND for Parkinson's.
" So, investors shouldn’t think we’ve abandoned the PD at all. And then I think as the IND type data starts emerging we’ll have a much clearer idea of exactly how this molecule should be applied. And I would imagine that somewhere in mid to late 2015, something like that, would be where we’d be starting to dialogue with the FDA about how a clinical study could look, and should look. "
I'd still like to know when they stated they will initiate the Eltoprazine 2b trial in 1H/2014? I can't even imagine what the stock price will be when that PR hits.